ARTHROPLASTY
Intravenous dexamethasone associated with reduction in time to discharge readiness post-THA, not TKA
J Arthroplasty. 2018 Nov;33(11):3429-3436. doi: 10.1016/j.arth.2018.07.013164 patients scheduled for either total knee arthroplasty or total hip arthroplasty were randomized to perioperative intravenous administration of either dexamethasone 8mg or placebo. Primary outcome was time to discharge readiness. Results demonstrated a significant reduction in time to discharge readiness with the use of IV dexamethasone among patients who underwent total hip arthroplasty, though no significant difference was observed between IV dexamethasone and placebo in patients who underwent total knee arthroplasty. In addition, overall length of hospital stay did not significantly differ between groups in either hip or knee arthroplasty patient cohorts.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
